Legal Analysis: Octreotide Acetate Injection and Sandostatin are medically insured drugs, and they are classified as Class B drugs in the national medical insurance.

However, it should be noted that due to different regions, the scope of medical insurance may also be different. It is recommended to refer to the relevant local medical insurance policies.

The main ingredient of Sandatin Octreotide Acetate Injection is octreotide acetate.

It belongs to pituitary hormones and related drugs, and is a colorless and clear liquid.

The pharmacological effects of octreotide are similar to those of somatostatin, but the effects last longer.

Inhibits the pathological increase in secretion of growth hormone and peptides of the gastroenteropancreatic endocrine system.

Legal basis: "Interim Measures of the People's Republic of China and the People's Republic of China for the Administration of Basic Medical Insurance Drugs" Article 3 The scope of basic medical insurance drugs is managed through the formulation of the "Basic Medical Insurance Drug Catalog" (hereinafter referred to as the "Drug Catalog"), in compliance with the "Drug List"

The cost of drugs in the Catalog shall be paid by the basic medical insurance fund in accordance with national regulations.

The "Drug Catalog" implements generic name management, and drugs with the same generic name in the "Drug Catalog" automatically fall within the payment scope of the basic medical insurance fund.